Kura reports additional Phase II data for tipifarnib in SCCHN

Kura Oncology Inc. (NASDAQ:KURA) reported updated data from six evaluable patients with v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS)-mutant relapsed or refractory squamous cell carcinoma of the head and neck (SCCHN) in a Phase II trial showing that tipifarnib led to five partial responses, plus one case of stable disease. Specifically, one patient who previously had stable disease converted to a partial response. Data were presented at the Multidisciplinary Head and Neck Cancers Symposium in Scottsdale.

Kura plans to start a Phase III trial of tipifarnib to treat HRAS-mutant SCCHN this year...